# Buprenorphine for Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines

> **NCT01671410** · PHASE1 · COMPLETED · sponsor: **Thomas Jefferson University** · enrollment: 11 (actual)

## Conditions studied

- Neonatal Abstinence Syndrome

## Interventions

- **DRUG:** oral morphine
- **DRUG:** sublingual buprenorphine

## Key facts

- **NCT ID:** NCT01671410
- **Lead sponsor:** Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2016-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01671410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01671410, "Buprenorphine for Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01671410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*